CompletedPhase 1NCT03430349

Phase 1 Novel Live Attenuated Serotype 2 Oral Polio Vaccine Study in Inactivated Polio Vaccine (IPV) Primed Adults

Studying Poliomyelitis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Pierre Van Damme
Principal Investigator
pierre van damme, MD,PHD
centre for the evaluation of vaccination
Intervention
Novel OPV2 candidate 1(biological)
Enrollment
30 target
Eligibility
18-50 years · All sexes
Timeline
20172017

Study locations (1)

Collaborators

Bill and Melinda Gates Foundation · Centers for Disease Control and Prevention · PATH · Celerion

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03430349 on ClinicalTrials.gov

Other trials for Poliomyelitis

Additional recruiting or active studies for the same condition.

See all trials for Poliomyelitis

← Back to all trials